Orbital Therapeutics, a company focused on enhancing global health by unleashing the full potential of RNA medicines to treat human disease, announced the successful closing of $270 million Series A financing.
SystImmune Inc. has announced the creation of its Clinical Science Advisory Committee, appointing Dr. Hope Rugo, M.D., Dr. Sara Tolaney, M.D., M.P.H, Dr. Pasi Jänne, M.D., Ph.D., MMSC.
Sanofi announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to Sanofi’s proposed acquisition of Provention Bio, Inc.
Epsilogen Ltd, a global leader in the development of novel immunoglobulin E antibodies to treat cancer, announced three new senior hires in what is a significant expansion of their management team.
Epsilogen announces significant expansion of management team with three new senior hires Read More »
Huma Therapeutics and UCB are partnering to offer a digital technology solution to help patients with the rare disease, Myasthenia gravis, better understand and manage their condition with the support of their clinician.
Nicox SA announced that studies highlighting nonclinical data on NCX 470 and NCX 1728 have been presented at the Association for Research in Vision and Ophthalmology Annual Meeting 2023 being held April 23-27, 2023 in New Orleans, LA, United States.
New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023 Read More »
J INTS BIO announced the poster presentation of its novel, orally administered TKI ‘JIN-A04’ targeting NSCLC with HER2 exon 20 insertion mutation at the annual meeting of the American Association of Cancer Research 2023, which was held in Orlando, USA from April 14 to 19.
MGI Tech Co., Ltd., a global life science tools leader, announced its partnership with Shanghai-based JMDNA Biomedical Technology Co., Ltd. for DNBSEQ-T20×2, a sequencer that broke records for its ultra-high throughput and cost-efficiency.
MGI Secured First Corporate Order of Ultra-high Throughput Sequencer DNBSEQ-T20×2* Read More »
After the end of the quarter, we received very positive news in our BI-1206 project.
BioInvent International AB: Interim Report January-March 2023 Read More »
Alentis Therapeutics announced results from the multiple-ascending dose part of its first-in-human Phase 1 clinical study of ALE.F02 targeting Claudin-1.
